IR@PKUHSC  > 北京大学首钢医院  > 泌尿外科
学科主题临床医学
Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension
Na, Yanqun2; Ye, Zhangqun3; Zhang, Shanzhong1; Chinese Dutasteride Phase III
刊名CLINICAL DRUG INVESTIGATION
2012
32期:1页:29-39
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]URINARY-TRACT SYMPTOMS ; RISK-FACTORS ; MEN ; DIHYDROTESTOSTERONE ; OBSTRUCTION ; INHIBITOR ; DISEASE ; CANCER
英文摘要

Background: Dutasteride is a dual inhibitor of type I and type II 5 alpha-reductases and provides nearly complete suppression of dihydrotestosterone, which plays a key role in the aetiology and development of benign prostatic hyperplasia (BPH). Most knowledge about the efficacy and safety of dutasteride in BPH derives from three pivotal phase III studies conducted primarily in Caucasian populations.

Objective: This study aimed to evaluate the efficacy and safety of dutasteride in Chinese adults with symptomatic BPH.

Methods: This was a randomized, double-blind, parallel-group, placebo-controlled study conducted over 6 months, followed by an open-label extension of 12 months. A total of 253 BPH subjects with a total prostate volume (TPV) of >= 30 cm(3), a maximal urinary flow rate (Q(max)) between 5 and 15 mL/s, and an American Urology Association Symptom Index (AUA-SI) score of >= 12 units were randomized to dutasteride 0.5 mg/day orally or matching placebo treatment in a 1: 1 ratio. After 6 months, eligible subjects who volunteered to enter the open-label extension received dutasteride 0.5 mg/day orally. Changes in TPV, Q(max) and AUA-SI as well as drug safety were evaluated.

Results: Dutasteride significantly reduced mean TPV compared with placebo at 3 and 6 months (both p < 0.05). At 6 months, mean TPV decreased by 17.14% versus 3.71% in the dutasteride and placebo groups, respectively. Numerically higher improvements in Q(max) and AUA-SI were observed in the dutasteride group at 3 and 6 months, but there was no statistically significant difference between treatment groups. However, ad hoc analysis indicated that, at 6 months, significantly higher proportions of subjects in the dutasteride group experienced a Q(max) improvement of >= 3 mL/s, or an AUA-SI improvement of >= 1 unit, compared with the placebo group (both p < 0.05). According to these criteria, the Q(max) a responder rates were 33.63% and 19.83% in the dutasteride- and placebo-treated groups, respectively, and the AUA-SI responder rates were 87.61% and 76.92%, respectively. During the open-label extension, continuous improvements in TPV, Q(max) and AUA-SI were noted in both groups. Dutasteride was well tolerated with a low incidence of treatment-related adverse events over 18 months.

Conclusion: Dutasteride was effective compared with placebo in the treatment of symptomatic BPH among Chinese patients. The efficacy data from trials involving subjects of different ethnic origins showed some similarities. Dutasteride was generally well tolerated during the study period.

语种英语
WOS记录号WOS:000298826800003
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62397
专题北京大学首钢医院_泌尿外科
作者单位1.GlaxoSmithKline China, Dept Med, Shanghai 200001, Peoples R China
2.Beijing Univ, Affiliated Hosp, Beijing Shougang Hosp, Dept Urol, Beijing 100871, Peoples R China
3.Huazhong Univ Sci & Technol, Affiliated Hosp, Tongji Hosp, Dept Urol, Wuhan, Hubei, Peoples R China
推荐引用方式
GB/T 7714
Na, Yanqun,Ye, Zhangqun,Zhang, Shanzhong,et al. Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension[J]. CLINICAL DRUG INVESTIGATION,2012,32(1):29-39.
APA Na, Yanqun,Ye, Zhangqun,Zhang, Shanzhong,&Chinese Dutasteride Phase III.(2012).Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension.CLINICAL DRUG INVESTIGATION,32(1),29-39.
MLA Na, Yanqun,et al."Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension".CLINICAL DRUG INVESTIGATION 32.1(2012):29-39.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Na, Yanqun]的文章
[Ye, Zhangqun]的文章
[Zhang, Shanzhong]的文章
百度学术
百度学术中相似的文章
[Na, Yanqun]的文章
[Ye, Zhangqun]的文章
[Zhang, Shanzhong]的文章
必应学术
必应学术中相似的文章
[Na, Yanqun]的文章
[Ye, Zhangqun]的文章
[Zhang, Shanzhong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。